OA-4 inhibits osteoclast formation and bone resorption via suppressing RANKL induced P38 signaling pathway

B. Tian, A. Qin, Z. Shao, T. Jiang, Z. Zhai, H. Li, T. Tang, Q. Jiang, K. Dai, Ming Zheng, Y. Yu, Z. Zhu

    Research output: Contribution to journalArticlepeer-review

    13 Citations (Scopus)

    Abstract

    Osteoclasts are one of the key therapeutic targets for a variety of orthopedic diseases such as osteoporosis and osteoarthritis. In this study, we synthesized a novel compound N-(3-(cyclohexylcarbamoyl) phenyl)-1H-indole-2- carboxamide (termed as OA-4) and investigated the effects of OA-4 on the differentiation and function of osteoclasts. OA-4 markedly diminished osteoclast differentiation and osteoclast specific gene expression in a dose-dependent manner. In addition, OA-4 dose-dependently suppressed osteoclastic bone resorption. Furthermore, we found OA-4 attenuated RANKL-induced p38 phosphorylation without affecting JNK or NF-κB signaling pathways. Collectively, we synthesized a novel compound OA-4 which can inhibit osteoclast formation and functions via the suppression of p38 signaling pathway. © 2014 Bentham Science Publishers.
    Original languageEnglish
    Pages (from-to)641-649
    JournalCurrent Medicinal Chemistry
    Volume21
    Issue number5
    DOIs
    Publication statusPublished - Feb 2014

    Fingerprint

    Dive into the research topics of 'OA-4 inhibits osteoclast formation and bone resorption via suppressing RANKL induced P38 signaling pathway'. Together they form a unique fingerprint.

    Cite this